Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease.
IVIG
MOGAD
acute treatment
effectiveness
outcomes
safety
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
10
8
2023
pubmed:
11
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown. The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks. A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment. Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
Sections du résumé
BACKGROUND
The potential therapeutic benefit of intravenous immunoglobulins (IVIGs) for acute attacks of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is unknown.
OBJECTIVE
The objective was to describe the outcomes of IVIG treatment for acute MOGAD attacks.
METHODS
A retrospective observational study involving seven tertiary neuroimmunology centers. Data collection included patients' demographics, Expanded Disability Status Scale (EDSS), and visual acuity (VA) before the attack, at the nadir of the attack before IVIG treatment, and at follow-up visits ⩾3 months after treatment.
RESULTS
Thirty-nine patients were included, of which 21 (53.8%) were female. The median age was 23 years (range 5-74 years), and the median disease duration was 4 months (range 0-93 months). The most common type of attack treated with IVIG was isolated optic neuritis (ON) (unilateral
CONCLUSION
IVIG may be an effective treatment option for acute MOGAD attacks. Further prospective studies are warranted to validate our results.
Identifiants
pubmed: 37431144
doi: 10.1177/13524585231184738
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Myelin-Oligodendrocyte Glycoprotein
0
Autoantibodies
0
Types de publication
Observational Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1080-1089Subventions
Organisme : NINDS NIH HHS
ID : R01 NS113828
Pays : United States